Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Xanomeline Prodrug,Trospium Prodrug
Therapeutic Area : Psychiatry/Psychology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Terran Announces Develop of TerXT, Xanomeline &Trospium Prodrugs for Schizophrenia
Details : TerXT, is a small molecule combination of novel prodrugs of xanomeline and trospium designed to enable fixed-dose combinations for once-daily oral administration for the treatment for schizophrenia.
Product Name : TerXT
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 20, 2024
Lead Product(s) : Xanomeline Prodrug,Trospium Prodrug
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : N,N-dimethyltryptamine is a psychedelic tryptamine, non-selective agonist for 5HT2a receptor being developed as a therapy for patients with neurological & mental illness.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
March 02, 2023
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tolebrutinib
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : old Sano
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Terran Biosciences Announces Licensing Deal with Sanofi for Two Late-Stage CNS Pipeline Assets
Details : Terran plans to quickly advance the development of the lead SAR442168 and other assets for neurological and psychiatric indications, which include several novel applications where there is a large unmet medical need.
Product Name : SAR442168
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 21, 2022
Lead Product(s) : Tolebrutinib
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : old Sano
Deal Size : Undisclosed
Deal Type : Licensing Agreement